Skip to content
- PDGFRß is an essential therapeutic target for BRCA1-deficient mammary tumors.
- Bai F, Liu S, Liu X, Hollern DP, Scott A, Wang C, Zhang L, Fan C, Fu L, Perou CM, Zhu WG, Pei XH.
- Breast Cancer Res. 2021 Jan 21;23(1):10. doi: 10.1186/s13058-021-01387-x.
- The Prognostic Relevance of Poly (ADP-Ribose) Polymerase Expression in Ovarian Cancer Tissue of Wild Type and BRCA-Mutation Carrier Patients.
- Molnár S, Vida B, Beke L, Méhes G, Póka R.
- Diagnostics (Basel). 2021 Jan 19;11(1):E144. doi: 10.3390/diagnostics11010144.
- Tumor-Infiltrating Lymphocyctes in Triple-Negative Breast Cancer: Update for 2020.
- Brown LC, Salgado R, Luen SJ, Savas P, Loi S.
- Cancer J. 2021 Jan-Feb 01;27(1):25-31. doi: 10.1097/PPO.0000000000000501.
- PARP Inhibitors in Triple-Negative Breast Cancer Including Those With BRCA Mutations.
- Layman RM, Arun B.
- Cancer J. 2021 Jan-Feb 01;27(1):67-75. doi: 10.1097/PPO.0000000000000499.